Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral …

… arm with biopsy-proven NASH and pre-diabetes or T2DM; primary endpoint to measure NASH resolution with no worsening of fibrosis; Poxel to host …

Read more at www.businesswire.com

Show More

Related Articles

Back to top button